Smith & Nephew ACTICOAT 7 Antimicrobial Barrier Dressing, 6" x 6" (20241)

IMAGE DISCLAIMER: PLEASE READ THE PRODUCT DESCRIPTION CAREFULLY. Do not order based on the image alone. The image displayed may not represent the specific product you are ordering.

SMITH & NEPHEW INC

Smith & Nephew ACTICOAT 7 Antimicrobial Barrier Dressing, 6" x 6" (20241)

Name: Smith & Nephew ACTICOAT 7 Antimicrobial Barrier Dressing, 6" x 6" (20241)
Brand: SMITH & NEPHEW INC
SKU: 5420241
Price: 85.35 USD
Availability: InStock

SKU: 5420241

$85.35

Sold by: 1 Each Box of 5 each

Item number: 5420241

Product variants

Need to know stock before placing an order?

Feel free to Email us!!

Product Description

Smith & Nephew ACTICOAT 7 Antimicrobial Barrier Dressing, 6" x 6".

For use over full and partial thickness wounds such as leg ulcers, burns and recipient skin grafts.

ACTICOAT consists of two outer layers of nanocrystalline silver-coated polyethylene net and an innner absorbent layer. ACTICOAT 7 consists of three nanocrystalline silver-coated layers and two inner layers, for seven day efficacy.

ACTICOAT 7 Antimicrobial Barrier Dressing

A dressing utilizing advanced silver technology to help create an optimal wound environment.

Features:

Rayon/polyester core helps manage moisture level and control silver release.
Silver-coated high-density polyethylene mesh facilitates the passage of silver through the dressing.
The nanocrystalline coating of pure silver delivers antimicrobial barrier activity within 30 minutes - faster than other forms of silver.
NUCRYST Pharmaceutical's antimicrobial technology is able to produce silver-coated polyethylene films that can release an effective concentration of silver over several days. Thus, as silver ions are consumed, additional silver is released from the dressing to provide an effective antimicrobial barrier. This patented silver-based antimicrobial technology can be applied to a wide range of medical devices including wound dressings, certain types of catheters and various implants to prevent infection. This technology was first applied to burn wound dressings because burns present a very severe risk of infection.

Benefits:

Delivers fast-acting, long-lasting antimicrobial barrier control.
Effective barrier which may assist in preventing contamination of the wound.
Laboratory studies show that the ACTICOAT 7 dressing kills micro-organisms faster than conventional products such as silver sulfadiazine (1 percent cream) or silver nitrate (0.5%) solution. It has also been shown in-vitro to provide protection against more than 150 pathogens. The pathogens tested in the lab include very resistant strains of bacteria such as antibiotic-resistant strains of Pseudomonas, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus and fungi. These pathogens have been known to sweep through a hospital and infect a great many patients with already weakened immune systems. Infections contracted during hospitalization caused by these so-called superbugs and other organisms cost North American taxpayers an estimated $18 billion a year in additional hospital care.
ACTICOAT 7 is versatile. The dressings can be cut to the desired shape and size to wrap around all body parts.
The sustained release of silver also means fewer dressing changes, resulting in less exposure of the wound bed to the environment. This reduces the risk of infection, which lowers hospital costs.
ACTICOAT 7 is cost-effective because it can be left on wounds for up to 7 days.

Indications

ACTICOAT 7 Antimicrobial Barrier Dressing is an effective barrier to bacterial penetration. The barrier function of the dressing may help reduce infection in partial and full thickness wounds including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first- and second-degree burns, and donor sites. ACTICOAT 7 dressings may be used over debrided and grafted partial thickness wounds.

Precautions

For external use only.
ACTICOAT 7 is not compatible with oil-based products, such as petrolatum.
Avoid contact with electrodes or conductive gels during electronic measurements, e.g. EEG and ECG.
In patients undergoing MRI (Magnetic Resonance Imaging) ACTICOAT must be removed from the area within the anatomical field being imaged. If ACTICOAT is being used on any area not within the image field, it may remain in place during the MRI.
Avoid exposure to temperatures above 50 degrees C. Protect from light.
Do not use if product color is not uniform.
Do not use contents if pack is opened or damaged.